Led by Erasmus MC in the Netherlands, the project ‘Unravelling host-pathogen pathways in mycetoma: the route towards novel diagnostic tools and therapies for controlling mycetoma globally (UNRAVELMy)’ and is the first of its kind large-scale fundamental research study for mycetoma, a fungal infection that is one of the world’s most neglected diseases.
This international collaboration will create a large biobank of mycetoma samples, bringing together research institutions in Sudan, Senegal, Belgium, Denmark, Ireland, the Netherlands, Switzerland, and the United Kingdom. By studying the fungus and the human immune response, the project aims to identify biological markers that could help improve diagnosis, monitor whether treatments are working, and identify new targets for drug development.
Despite recent progress, including the DNDi-led development of fosravuconazole in Sudan, treatments for eumycetoma still require months of treatment and often surgery, with significant room for improvement.
Mycetoma is neglected not only in terms of available treatments, but also in the understanding of the disease itself. Investing in fundamental research is therefore essential to build the scientific foundations needed to develop the next generation of diagnostics and treatments, and ultimately improve outcomes for patients.
More information on the project: Mycetoma Translational platform | DNDi
Novo Nordisk announcement: No easy answers: European research consortia take on major challenges – Novo Nordisk Fonden